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Summary.-Cancer cells should be seen not as exclusively a problem in cell pro-
liferation, but rather as a problem combining the processes of proliferation and
differentiation, hence the phrase introduced in 1968: "oncogenyis blocked ontogeny".
Cancer tissues resemble foetal tissues in many ways but they differ from foetal
tissue in being unable to "recapitulate the total programme leading to an orches-
trated collection of organism-serving cells" that are programmed "to make the
organ as adaptive as possible to the range of environmental variations in which it
evolved". Citing the "Osgood Principle" from the 1950's, recent supporting evidence
was described, in which the most mature differentiated cells exert positive and nega-
tive feedback upon the proliferation oftheirprogenitor stemcells. Advanced examples
in the haemopoietic series were drawn from the work of Sachs, Metcalf, Till and
McCulloch, and Kurland and Moore. The blocked ontogeny hypothesis was further
elaborated in the concept of "partially-blocked ontogeny", which is intended to
describe a situation in which highly differentiated slowly growing tumours contain
some cells which have left the proliferating pool to differentiate along the normal
pathway, but are blocked somewhere short of the final organism-serving state, in
harmony with earlier suggestions by Osgood, by Pierce, and by Sachs.
PHENOTYPIC diversity among cancers is
expressed in terms of variable rates of cell
proliferation, variable degrees of differen-
tiation, and variation in the metabolic
pathways that make proliferation possible.
Thus, phenotypic diversity increases the
complexity of the cancer problem immea-
surably. There is little doubt that if all
cancers grew at the same rate and used the
same metabolic pathways, the problem
would have been solved by now.
Phenotypic diversity in normal tissues
may occur by two mechanisms that can
be thought of as representing the ex-
tremes of the range of possibilities: (1)
in the evolution of species, diversity arises
by adaptive mutations in the DNA com-
plement that makes up the genotype, and
(2) phenotypic diversity can arise through
ontogeny, the total programme ofdifferen-
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tiation, which has been accepted as a pro-
cess that alters the availability but not the
information content of the total DRNA com-
plement. Whether the assumption of dif-
ferentiation without alteration ofthe DNA
sequences (mechanism 2) can be main-
tained is still a matter of speculation. In
any case, we can benefit by attempting to
explain the phenotypic diversity that oc-
curs among those cancers that have in-
curred the least possible change in the
genome. Among the more than 40 Morris
hepatomas there are several that have the
normal diploid number of chromosomes,
though it is not claimed on that basis that
the genome has not been altered (Potter,
1968a, b).
I suggest that phenotypic diversity
among cancers can be explained without
the need to involve extensive change in thePROFESSOR VAN RENSSELAER POTTER
genotype, although change certainly occurs
during the natural history of neoplastic
disease when, for example, drug-sensitive
tumours become resistant. Even in the
absence of extensive genetic alteration, I
believe that there are a multitude ofstages
in differentiation, prior to the terminal
stage, that, if prevented from advancing
toward the terminal stage, will cause a cell
to retain its capacity to re-enter the pro-
liferative cycle. Thus, vast phenotypic
diversity may be explained by the occur-
rence of only one or a few genetic altera-
tions that can be effective in blocking
differentiation in one or several steps, with
results that are compatible with return to
proliferation. Along with many others, I
believe that cancer is a disease of differen-
tiation.
The problem reduces to what I have re-
ferred to (1968a) as the "minimal devia-
tion" concept, which, in turn, can be ex-
pressed in the framework of the process of
differentiation in the phrase "oncogeny is
blocked ontogeny" (Potter, 1968a, b;
Potter et al., 1972), aphrasethatAlexander
(1972) felt was no more than a restatement
of the "many similarities between foetal
and cancer tissue". The phrase is, however,
intended to be much more than a restate-
ment of similarities. The point is not that
cancer tissue resembles foetal tissue in
some respects, it is that in important ways
cancer tissue does notresemblefoetaltissue.
The difference lies in the word blocked. An
organ from a foetal or newborn animal
consists of a population of cells that are
participating in an organized and or-
chestrated programme which takes them
through a sequence of changes that are
constantly tailored to make the organ as
adaptive as possible to the range of en-
vironmental variation in which it evolved.
In contrast, although a clonal neoplasm
that develops from a cell in a particular
organ may differentiate into a population
that has much ofthe phenotypic variation
seen in a population of normal cells from
the same organ, it will not recapitulate the
total programme leading to an orches-
trated collection of organism-serving cells,
because, in nmyearlierwords, the canceris a
case of "blocked ontogeny", and I mean to
imply that the total programme ofnormal
ontogeny is blocked somewhere because of
a change in one or more chromosomal or
extrachromosomal DNA sequences in the
original cellfromwhichtheneoplastic clone
was derived. The concept of blocked onto-
geny does not require that all the descen-
dants ofthe clone must bear the genotypic
defect, nor does it require that the block in
ontogeny is necessarily at the embryonic
or foetal stage of ontogeny for the tissue
of origin. The block could conceivably
come at any point between the dividing
cell and the terminal stage of differentia-
tion. It must be clear that the concept of
blocked ontogeny has to include "early-
blocked ontogeny", that is, exponential
proliferation of stem cells that can give
rise only to two cells both of which con-
tinue to proliferate without further dif-
ferentiation. In addition, the concept must
include "partially blocked ontogeny" in
which a substantialfraction of the tumour
cell population undergoes extensive dif-
ferentiation but does not progress to the
normal organized terminal state.
This concept was stated by me (Potter,
1968b) as follows: "There may be an ex-
tremely large number of intermediate
stages between the committed hepatocyte
and the adult hepatocyte, wherein a
mutant gene could result in a blocked de-
velopment and produce a clone of cells
with a normal chromosome number, but
with a propensity for continued cell repli-
cation, and with a resistance toward nor-
mal feedback controls so that the observer
would call it a cancer." At that time it was
also stated: "We have now reached a stage
in experimental cancer research where it is
possible to work with a variety of 42-
chromosome* hepatomas and to show that
they have diverse phenotypes. We feelthat
it is feasible to attempt to rationalize the
diversity that occurs at this stage oftrans-
* The normal diploid ntumber in the rat.
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formation. The experimental task need not
be the rationalization ofthe bizarre pheno-
types that may appear where cancer cells
progress to highly aneuploid genotypes, in
which any kind of a non-essential change
can occur so long as it permits the cancer
cell to continue replicating. At that level
of random change it would be asking too
much to rationalize the meaning of all the
enzyme patterns that are compatible with
malignancy."
Five years later, in 1973, addressing
Princess Takematsu at the conclusion of
the Symposium on Differentiation and
Control of Malignancy of Tumor Cells, I
remarked that "a comprehensiveand pene-
trating understanding of the molecular
and biological nature of cancer is very near
at hand, so near that when we look back
4 or 5 years from now it may be difficult to
say exactly which discoveries were most
important in gaining this understanding.
Later perhaps a clearer perspective will be
gained. But I must caution you thatunder-
standing is not synonymous with conquer-
ing the disease" (Potter, 1974). On that
occasion a hint of the present discussion
was also indicated (ibid., p. 186).
Today, these 4 or 5 years have passed
and I must attempt to justify the two-fold
claim that understanding would be near
at hand, and that the contributing con-
cepts and experiments would come from
more than a few individuals. My method
will be to present an extended introduc-
tion, in which a number of advances will
be mentioned, and to conclude with a brief
mention of some work in my own labora-
tory seen against the background as
described.
PHENOTYPIC DIVERSITY IN 1956
In discussing phenotypic diversity, a
useful point of departure is a symposium
sponsored by the American Cancer Society
in March 1956 entitled: "A CriticalApprai-
sal of the Biochemical Characteristics of
Morphologically Separable Cancers" (Can-
cer Res., 16, 639-724). It could have had a
simpler title: "Differences among Can-
cers." The report is noteworthy for the
extent of the commentaries provided, and
for the expressions of points of view at a
time that preceded the era of molecular
biology as we now know it, indeed, before
the insights permitted by the availability
of the Morris hepatomas, of which more
later.
Diversity in pathology
I was tremendously influenced by a
pathologist (Steiner, ibid. p. 681) whose
extensive presentation of coloured slides,
showing stained microscope sections, was
unfortunately not presented or described
in the final report. However, the forceful
presentation of personal views remains in
print. ". . . are neoplasms one basic disease
or are they many different diseases? The
problem whether the neoplastic state has
an essential defect commonto alltumours,
formerly only of theoretical interest to a
few, has become dominant to investigators
in human etiological agents, cancer tests,
and chemotherapy.... Every tumour cell
is a composite of normal and abnormal
(neoplastic) in varying proportions. They
are morphologically recognized as tumour
by their abnormalities, but the residual
normal features indicate their origin . . .
... the changes ... form the basis for
tumourdiagnosisfromstainedtissues, even
though the chemical interpretations ofthe
materials visualized are onlypartlyknown.
The quantity and spatial distribution of
the chemical constituents appear altered
in tumour cells. No two tumours are ever
alike in this regard, unlike normal tissues.
Whether this visible abnormality and diver-
sity represents quality as well as quantity of
chemicals is not known. It nevertheless
illustrates greatdiversityintumours" (italics
added).
"On purely clinical grounds it [cancer]
shows both great diversity and a unifying
principle.... Cutaneous, gastric, and uter-
ine cancers appear to be separate diseases.
They are diagnosed and treated by differ-
ent methods and often by different special-
ists. However, constantly lurking in the
physician's mind is an awareness of a
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unifying basic biological characteristic
shared by all tumours, namely, that of a
relentless cell proliferation and its disas-
trous consequences."
To my knowledge Steiner was the first
oncologist to have the courage to say in
print that "No two tumours are ever
alike." Even though he spoke as a pathol-
ogist, the inference might be drawn that
the statement applied to basic biochemical
differences and to therapeutic response.
Diversity in chemotherapy
Karnovsky (ibid., p. 698), speaking on
"Differences between Cancers in Terms of
Therapeutic Responses", concluded his
introduction as follows: "It can be con-
cluded at the outset of this talk, andwith-
out much thought, that cancers differ
greatly among themselves. This categorical
conclusion is not a promising one to the
therapist but, if true, it is so important
that it should be arrived at only at the
completion of a laborious analysis. It is
this great diversity among cancers, parti-
cularly in theunpredictability ofthethera-
peutic response in individual cases and in
the invariable development of resistance
to treatment in the responsive cases, that
I am discussing today." It may be recalled
by some that Dr Karnovsky died, avictim
of cancer, in 1969 (Burchenal, 1970) atthe
age of 55. Although the diversity he re-
ferred to still presents difficulties to the
therapist, the reference to "invariable de-
velopment ofresistance" would have to be
qualified, and in fact Dr Karnovsky lived
to see some of his own patients in whom
tumour cells were apparently all killed by
chemotherapy before the tumours could
develop resistance.
Diversity in biochemistry
Greenstein (ibid., p. 641) presented a
biochemical viewpoint beginning w-ith the
words: "The great and seemingly insuper-
able antithesis of unity and variety may
serve as the theme of the present discus-
sion." He went on to emphasize unity as
he developed the theme of convergence to
a uniform pattern of enzymes, a concept
that was correctly analysed by Weinhouse
(ibid., p. 654) as possibly applicable to late
generations oftumour cells after successive
transplantations, but not necessarily to
primary tumours which could retain many
features of their cell of origin. In the fol-
lowing discussion (ibid., p. 658) I presented
what amounted to the biochemical defini-
tion of phenotype as follows: "We think
that tissues can be characterized by the
kind and amount of enzymes that they
contain . . . It means that the characteri-
zation has to be framed in terms of the
spatial organization of enzymes in the cell
in nuclei, nucleoli, mitochondria, endo-
plasmic reticulum, RNA granules [today
called ribosomes], soluble enzymes, cell
and particulate surfaces, and units as yet
undiscovered [today add messenger RNA
and polysomes]. It means that the charac-
terization has to specify a particular point
on the time scale, both in relation to the
life ofthe tissue and relative to changes in
the environment [e.g., changes mediated
by hormones]. It means that we have to
recognize that tissues are nothomogeneous
with respect to celltypesandthat[enzyme]
values for tissues depend on the relative
proportions of cell types and their possible
interaction." Coming from the progenitor
of the homogenate technique (Potter and
Elvehjem, 1936), I think that statement
represents some progress in the 20 years,
1936-56, and moreover that it is a viable
statement today, 1978, 22 years later.
What has changed is not only the avail-
ability of new techniques (especially for
cell culture) and new parameters (cyclic
nucleotides, prostaglandins, new peptide
hormones, isoenzymes, etc.) but new ex-
perimental tumours, both primary and
transplantable in isologous hosts, in which
the properties ofthe primary tumour tend
to be preserved, e.g., the Morris hepatomas
(Morris and Meranze, 1974). Most fascinat-
ing ofall is the description ofnew enzymes
that regulate phenotypic expression. Their
presence or absenceper se is part ofpheno-
typic expression. These enzymes include
e.g. adenylcyclase, prostaglandin synthe-
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PROSTAGLANDIN ENDOPEROXIDES
Prostaglandins, Prostacyclin, Thromboxane A2
cAMP dependent cAMP independent
Specific Protein Kinases
NON-PHOSPHORYLATED ENZYME - ENZYME-PHOSPHATE
Isome active, some inactive) (some active, some inactivel
Specific Phosphatases
(regulation not clear)
FIG. 1. -Modulatiofl of enzyme activity by
cascading multistage controls. Modified
from Greengard (1978), Cohen (1973,
1976), Gorman et *tl. (1977) and Pace-
Asciak (1977). Cyclic AMP is formedI
through a variety of mechanisms not in-
volving prostaglandins, and there are pro-
tein kinases that do not depend on cyclic
AMP (Greengard, 1978).
tase (several components), the "newer"
enzymes, prostacyclin synthetase and
thromboxane A2 synthetase, all of which
are early components of multistage con-
trols, plus the late-stage controls known
as protein kinases and protein phospha-
tases. The literature describing all the ad-
vances in the biochemical regulation of
phenotype expression is too vast to be
cited at this point. Greengard (1978),
Cohen (1973, 1976), Gorman et al. (1977)
and Pace-Asciak (1977) are afewexamples.
However, the particular mechanisms
shown in Fig. 1 are relevant to the feed-
back systems to be discussed later.
THE EVOLUTION OF THEORY AND)
EXPERIMENT SINCE 1956
The cell cycle
To support the claim that understanding
ofthe nature ofcancer is near at hand, and
to single out the names of "more than a
few" individuals, is a task that is worthy
of a Hubert Lecturer, but one that I ap-
proach with trepidation and humility. I
have observed that, perhaps more than in
any other field, the bibliographies of re-
views of cancer research are studded with
references to the author's work, usually
5 .aMo
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FIG. 2. The cell cycle as originally proposed
by Howard and Pele in 1953. M=mitosis;
G1 =phase after mitosis and before DNA
synthesis; S=phase (luring which DNA is
synthesized, indicatedl by incorporation of
labelled thymidine (marked by asterisk);
G2=phase between S and M.
excluding many references that others
might think pertinent. I will necessarily
omit many names, but none intentionally,
and perhaps on another occasion I could
improve over the present effort.
In attempting to cover some aspects of
the last 20 years, I will describe models of
cell replication and differentiation. In my
opinion, models serve as "aids to commu-
nication" entirely apart from their relation
to reality (Potter, 1964).
The first model ofthe cell cycle was that
of Howard and Pelc (1953) who originated
the well-known model based on the
incorporation of radioactive thymidine
into DNA (Fig. 2).
It was not until 1963 that Lajtha, rea-
soning from a knowledge of events in
regenerating liver, introduced the concept
of another stage (Go) appended to the cell
cycle. Fig. 3 is developed from his sug-
gestion. The Go concept was introduced to
account for the fact that a period of about
16 to 18 helapses afterpartialhepatectomy
in rats before the hepatocytes begin to
enter the S phase (DNA synthesis). In an
adult rat the great majority of the liver
cells are not proliferating, and Lajtha pro-
posed the term Go in preference to assum-
ing that the cells are merely in a prolongedPROFESSOR VAN RENSSELAER POTTER
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FIG. 3. The cell cycle of Fig. 2, with addition of 2 new terms (Go and GT) directly related to dif-
ferentiation. Go was a term introduced by Lajtha in 1963 to indicate a condition distinguished from
G1 in that the cell is not preparing for DNA synthesis. Here Go is defined as any stage of differentia-
tion, up to and including the nth stage, provided that the cell can still return to G1 and complete
a cycle of proliferation at the same level of differentiation or at a more specialized level. The Go
stage at any level could undergo further specialization until it reached a terminal stage (GT) at
which it could no longer return to G1. The GT cell is conceptually a Gon+1 cell in the sense that the
Gonth is the last cell in the Go series that can return to a G1 stage. Rates k1 and k2 are included
for comparison with Fig. 4. However, in the present chart, and particularly in regenerating liver,
in which events begin from Go, kl might apply to Go-+G1 and k2 might apply to Go-iGT.
G1 stage ofthe cell cycle. Essentially 100%
of the hepatocytes in a young adult rat
(e.g., 90 days old) are capable ofreturning
from Go to G1, S, G2 and mitosis. In an old
rat (e.g., at 2-5 years) this is not the case,
as it has been estimated by Stocker and
Heine (1971) that as many as 69% of the
hepatocytes cannot return to G1. Thus, it
seems appropriate to me to integrate the
Go concept into the cell cycle as shown in
Fig. 3, which depicts the GO stage as a non-
proliferating cell that passes through inter-
mediate stages of differentiation, that
eventually culminate in a stage ofterminal
differentiation that I have labelled GT to
indicate that, unlike cells in GO, it cannot
return to G1 and the proliferating pool, and
that it culminates in the death of the cell.
In this way I wish to restrict the definition
ofa Go cell by defining it as a cell that can,
regardless ofits other properties, return to
the G1 stage. There must be many diverse
cells in Go that are capable ofreturning to
G1, and the GT fraction provides for those
that cannot. For comparison, I also show
a model (Fig. 4) used by Mendelsohn and
Dethlefson (1973) and by Steel et al. (1966)
to describe tumour growth. This latter
model seems to make no provision for the
occurrence of a Go tumour cell.
Although non-proliferating, the Go cell
of, say, a young adult mammal can be de-
fined as a cell that has 3 options: (1) it can
return to the G1 stage and re-enter the
proliferativecycle,(2)itcanundergofurther
differentiation (development?) to new Go
states, by making new parts of its genome
available, or (3) it can remain in the same
Go state but with variable production
[phenotypic expression] of the so-called
luxury molecules in response to organismic
demands. Of these possibilities that which
provides the best agreement with the con-
cept of differentiation and its role in the
development of neoplasia is possibly (2),
the maturation to a biochemically or
morphologically new Go that can still re-
enter the proliferating cycle. Indeed,
instead of thinking of 3 discrete classes of
behaviour, it would be more appropriate
to inquire how much time a Go cell in any
given series spends in a phenotypically
steady state before switching to prolifera-
tion or to greater specialization, and to
what extent these activities can occur con-
currently. Recent advances in the under-
standing of the control mechanisms in-
volved in the regulation of proliferation
vis-a-vis differentiation have come from
studies of the haemopoietic system.
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FIG. 4. Simplified kinetic model of tumour
growth. A model presented by Mendelsohn
and Dethlefson (1973). See also Steel et al.
(1966). P is the proliferating pool of cells, Q
thenon-proliferating pool, and kl, k2, k3 and
k4 are rate constants. The model appears
not to provide for Go cells in the Q pool, i.e.
for a conversion of non-proliferating cells
to the cell cycle as in Fig. 3.
Spleen-colony-forming cell8
A new line of research began when Till
and McCulloch (1961) were able to show
that the injection of suspensions of single
cells from mouse marrow into heavily irra-
diated mice produced macroscopic colonies
of cells in the spleen at the rate of about 1
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per 104 injected. The colonies were shown
to be clonal in nature; that is, derived from
a single cell (Becker et al., 1963; Abramson
etal., 1977). In 1964, further studies by the
Toronto group proposed a stochastic model
for the early events in a spleen colony, to
explain how a clone from a single cell could
develop into all the known components of
the haemopoietic system (Till et al., 1964).
Nine years later, they reaffirmed their
original proposition (Korn et al., 1973).
According to the stochastic model: "The
decision of pluripotent stem cell (S) to self
renew, differentiate to the erythroid line
(E) or differentiate to the precursor of the
granulocyte line (G) is a random event
determined by the 3 probabilities ps, PE
and PG respectively" (Korn et al., 1973).
Whilethis model does not include feedback
controls it was not developed for the
steady-state conditions, since the early
events in the spleen colony occur in
a heavily irradiated animal, in which
cells capable of exerting feedback have
been greatly depleted. The stochastic
MA
.,GG
GE etc.
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(erythrocyte)
%. S
FIG. 5.-Stochastic early events in a clone from a spleen colony-forming unit (CFU-S) with no fee(l-
back indicated, modified from Korn et at. (1973) using notations from Figs. 2 and 3. Superscripts
S, E, G, MO, and MA indicate CFU-S, erythroid linie, granulocytic line, monocyte and macrophage
respectively. Initial probabilities indicated by ps, PE and PG. In addition, the probability con-
cept is extended to indicate two options for every cell in Go: return to G1 or advance toward GT.SPROFESSOR VAN RENSSELAER POTTER
rno(lel represents the built-in probabilities
under whatever feedback may exist in the
irradiated animal, and it is understood
that the probabilities change as feedback
takes over the direction of the outcome.
Thus, it was noted that "even though at
late times erythroid cells are in the great
mnajority in the colonies, the decision to
differentiate to the granulocyte line is
favoured over the erythroid line by a ratio
ofabout 10 to 1". Fig. 5 is a representation
ofthe stochastic model modified from that
pr-esented by Korn et al. (1973) by relating
it more closely to Figs. 2 and 3.
At the time of their report, the Toronto
authors commented that "the direct study
in vivo ofthe early events of a differentiat-
ing system, such as haemopoiesis, is not
feasible at present. Cells or cell lines arenot
immediately recognized or identified by
morphological or functional criteria as
being committed to develop in certain
directions, but must propagate and dif-
ferentiate to a stage where such identifica-
tion becomes possible" (Korn et al., 1973).
Further evolution of the experimental
approach suggests that early changes may
soon be visualized in individual cells by the
techniques of immunofluorescence (Tsu-
kada and Hirai, 1975) with concomitant
autoradiographic visualization of cells in
which DNA is labelled by 3H-thymidine
(Howard and Pelc, 1953; Lajtha, 1963;
Stocker and Heine, 1971; Mendelsohn and
Dethlefson, 1973; Steel et al., 1966). Re-
markable increases in the understanding
of the haemopoietic system were made
possible by the development of cell culture
techniques.
Colony-forming units studied by cell-culture
techniques
In 1965-67 as reviewed by Metcalf
(1973) and by McCulloch et al. (1974) 3
grouips began the study of the differentia-
tion of the pluripotent stem cell from
marrow by cell-cuilture techniques. These
developments occurred in the laboratories
ofPluznik and Sachs (1965, 1966) in Israel,
Bradley and Metcalf (1-966) in Australia
and Senn et al. (1967) in Canada. In the
beginning of the cell-culture studies, the
erythroid line, which had developed nicely
in the spleen colonies, failed to develop in
the culture dishes. However, in 1971 this
deficiency was corrected by the Axelrod
group (Stephenson et al., 1971). The de-
velopment of cell-culture techniques made
it possible to show that the stochastic
model of cell differentiation is overlaid by
several layers ofboth positive andnegative
feedback controls.
The Osgood Principle
Recent developments in the feedback
control of haemopoiesis represent the con-
firmation of what I should like to call the
Osgood Principle, which was first formu-
lated in 1950 and reviewed by Osgood in
1957 and 1959 with references to literature
on both inhibitors and stimulators. The
late E. E. Osgood was a haematologist,
whose unique cell-culture method was
published in 1955 (Osgood andKrippaehne,
1955). He stated (Osgood, 1957) the prin-
ciple "that with the majority of cell series
the homeostatic regulator is an inhibitor of
arithmetic cell division and is probably pro-
duced by the most chemically mature of the
differentiating cells of that series" (italics
added). This most chemically mature cell
is the cell that I label GT in Fig. 3. Osgood
continued: "somewhat earlier in the pro-
cess of differentiation an inhibitor of the
logarithmic division that constitutes the
growth process must be produced. If this
were the case, all that would be necessary
for unlimited growth in other words,
malignancy-would be the absence of the
inhibitor of logarithmic growth. The simp-
lest mechanism which could explain this
decreased production of inhibitor would
be the early death of the differentiating
cell before it reached the stage at which
the inhibitor was produced." This seems
to be another way of saying that "onco-
geny is blocked ontogeny" (Potter, 1968b).
In both reviews Osgood reasoned that "the
inhibitor must be relatively unstable" and
"only the cells immediately subjacent are
affected, indicating that the inhibitor must
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be relatively unstable. . ." This emphasis
on unstable inhibitors will be referred to
later in this section. Osgood designated
the stem cell ax and the next stage of dif-
ferentiation an n cell, pointing out that the
of cell could go to 2 ots or 1 ox+ 1 n cell, while
the n cell could only produce 2 n cells or
further differentiate with or without divi-
sion. In Fig. 3, I equate the Go cell with
Osgood's n cell, and wish to suggest that
one has to consider the fate ofapopulation
of Go cells, in the sense that from a com-
bination of individual possibilities (2G1,
2Go or IGo+±1G) an outcome of X% Go
and 100-X% G1 would be obtained.
Relating the Osgood Principle to the
cancer problem, a final quote merits atten-
tion. It was proposed that "any alteration
ofthe genetic material in the somaticalpha
cell of a series which leads to early death
of the corresponding n cell [and I would
add: "or which leads to a failure to mature
to the GT stage"] may result in a spectrum
of neoplasms of corresponding cellular
type, from the most acute, rapidly progres-
sive malignant tumour to the most slowly
growing benign tumour depending on how
early in the life span ofthe n cell death [or
a block] occurs" (Osgood, 1959). This pre-
diction has been illustrated by the case of
the Morris hepatomas, since they represent
a wide spectrum from poorly to highly
differentiated types in which phenotypic
diversity may be related to the concept of
partially blocked ontogeny. Osgood de-
veloped a method for "long-term mixed
cultures of human hemic cells" (Osgood
and Krippaehne, 1955; Brookes and
Osgood, 1959) but he never had access to
the modern approaches involving cells
embedded in soft agar and underlaid by
feeder layers of different cell types that
produce specific stimulators andinhibitors.
However, he visualized a therapeutic ap-
proach based on his principle in the state-
ment: "Only the replacement of the
normally gene-produced missing factors
necessary for a normal life span [i.e., ma-
turation to GT] ofthe n cell, . . . would lead
to a real control ofa malignant neoplasm."
This view has also been expressed by
Pierce et al. (1974): "Rather than kill
malignant stem cells, it is proposed that
studies should be undertaken to direct
their differentiation to the benign state"
and by Sachs: "A tissue culture line of
mouse myeloid leukaemia cells can be in-
duced to form colonies with normal dif-
ferentiation to mature macrophages and
granulocytes by [conditioned medium]
that contains MGI [a protein inducer also
known as CSF, colony stimulating fac-
tor]. . . Treatment with MGI may thus
be of potential value in the therapy of
leukaemia", Fibach et al., 1973. Further
studies by Sachs have continued to the
most recent number XIII under the
general heading "Control of Normal Dif-
ferentiation of Myeloid Leukaemic Cells"
(Maeda and Sachs, 1978). Elsewhere Sachs
stated: "Malignant cells blocked in various
stages of cell differentiation can be of value
in elucidating the mechanism of differen-
tiation and the blocks that can occur during
carcinogenesis. We have shown that some,
but not all, undifferentiated mammalian
myeloid leukaemic cells can be induced to
undergo differentiation to mature macro-
phages and granulocytes. . ." (Lotem and
Sachs, 1974) (italics added). It is clear that
the phrase "partially blocked ontogeny"
and the concept of neoplastic variation all
the way from complete to partiallyblocked
ontogeny is the working hypothesis of
Sachs and his colleagues, who owe me no
debt in this regard.
Positivefeedback controls ofcolonyformation
in the haemopoietic system in cell cultures
As mentioned earlier, thestudyofcolony
formation in cell cultures coincided with
the demonstration of stimulating factors
produced by differentiated cells near the
terminal point and exerting positive feed-
back on the earliest progenitors. Metcalf
(1973) has pointed out that "Colony for-
mation in vitro by both granulocytic and
macrophage cells is wholly dependent on
the presence of adequate concentrations
of a specific factor, given the operational
name, colony stimulating factor (CSF)."
The substance is a glycoprotein containing
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sialic acid (Stanley et al., 1975) and is ap-
parently identical with the factor called
MGJ in Fibach et al. (1973) or CSA by
others. It has been reported that CSF from
mouse cells is completely unable to replace
human CSF in its action on human target
cells (Kurland et al., 1978). The action of
CSF is apparently quite analogous to ery-
thropoietin (Gruber et al., 1977) which per-
forms similar functions in promoting the
erythroid line.
Negative feedback controls on colony
fornmation in cell cultures
In 1977, Broxmeyer et al. at the Sloan
Kettering Institute reported the elabora-
tion of colony-inhibiting activity (CIA) by
polymorphonuclear neutrophils (PMN)
and pointed out that the latter derive from
progenitor cells committed to granulocyte
and monocyte-macrophage differentiation
and stimulated by CSA (CSF, MGI). They
visualized a combined positive and nega-
tive feedback system designed to promote
homeostasis in the whole animal. Brox-
meyer et al. (1976) referred to studies on
leukaemic patients whose PMN failed to
elaborate the negatively acting CIA. With-
in a very short time, colony-inhibiting
activity was demonstrated with prosta-
glandin E1 (PGE1). First came a report by
Kurland and Moore (1977a) studying the
inhibitory action of the pure substance
PGE1 which was demonstrably active at
10-10 M at all concentrations of CSF, while
10-5 M PGE1 produced total inhibition of
colony production at all CSF concentra-
tions. This was quickly followed in Febru-
ary this year by a report from Kurland et
al. (1978) showing a direct relationship be-
tween CSF concentration and PGE pro-
duction. In addition, by using the soft-
agar technique, with marrow cells in the
upper layer separated by a cell-free middle
layer from the mononuclear leucocytes in
the lower layer, they were able to demon-
strate the homeostatic effect of the com-
bined production of CSF and PGE1, and
the release from colony-inhibiting action
when indomethacin was apparent and no
PGE1 was formed. Fig. 6 is my expression
of those relationships using the symbols
employed in Figs. 2 and 3. The data re-
produced from the 1978 report are shown
in Fig. 7. A further report on indomethacin
effects on normal and neoplastic cell lines
has also appeared (Kurland and Moore,
1977b). Indomethacin inhibits the synthe-
sis of prostaglandin endoperoxide and
subsequent derivatives (Fig. 1.).
With the reports that in some systems
prostacyclin is much more active than
PGE1, much less stable and a product of a
microsomal metabolism system (Gorman
et al., 1977; Pace-Asciak, 1977) further
studies with the short-lived prostaglandins
may be expected.
Of interest is a total haemopoietic
scheme by Kurland and Moore, in which
`."' s H(ve
Fio. 6. Feedback controls on the proliferation of the stem cell. A model based oIn the experiments
ofKurland et al. (1978) (data shown in Fig. 7) using the Go and GT symbols from Figs. 3 and 5, and
G1, S, G2 and M as in Fig. 2. CSF is colony stimulating factor; for other abbreviations (CSA and MGI)
see text. PGE is prostaglandin El(Kurland et al., 1978). (+)ve, positive feedback; (-)ve, negative
feedback. In(lomethacin is an inhibitor of the synthesis of prostaglandin endoperoxides and sub-
sequent products (Fig. 1). Note bidirectional positive feedback by CSF on stem cell and on PGE
synthesis in the cells that can produce CSF.
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Fia. 7.-Experiment demonstrating negative
feedback on proliferation of colony-
forming units in culture (CFU-C) by
mononuclear leucocytes, and its inhibition
by indomethacin. Data from Kurland et al.
(1978) with permission of the authors and
from The American Association for the
Advancement of Science. In the citedarticle
the authors also showed that production of
PGE was a function of CSF concentration.
The model in Fig. 6 is intended to des-
cribe the data in the above Figure. Note
the homeostatic level of colony numbers
attained in the absence of indomethacin
(controls) and the increasing number of
colonies in the presence of indomethacin,
when no PGE was formedl.
it is indicated that although prostaglandin
exerts negative feedback on the granulocy-
tic stem cell (CFU-C, colony forming unit
in culture) it exertspositivefeedback on the
proliferation of the pluripotent stem cell
(CFU-S) (Broxmeyer et al., 1976).
The above reports from the laboratories
of Metcalf, Sachs, Moore and Till and
McCulloch are a tiny fraction oftheir total
effort and the work ofothers (Dutcher and
Chieco-Bianchi, 1973) in experimental
haematology, a field with which I have not
developed familiarity. However, I have
described some recent developments for
two reasons: first, to serve as abackground
for an attempt to visualize similar develop-
ments in experimental liver carcinogene-
sis; and second, to support my prediction
in Tokyo in 1973 (Potter, 1974) that 4 or 5
years would result in great advances in the
understanding of differentiation in normal
and neoplastic cells.
STUDIES ON LIVER AND HEPATOMAS
The advances in the understanding of
differentiation and proliferation in the
haemopoietic system are by no means
equalled in the case of parenchymal liver
cells, although a large amount ofliterature
is accumulating (Tsanev, 1975). In the
case of carcinogenesis in liver, the experi-
mental material and techniques now avail-
able merit intensive work on the hypothe-
sis that in liver "oncogeny is partially
blocked ontogeny", for, paraphrasing the
opening words of a paper on myeloid
leukaemic cells by Lotem and Sachs (1974)
"[Hepatoma] cells blocked in various
stages ofcell differentiation can be ofvalue
in elucidating the mechanism of differenti-
ation and the blocks that can occur during
carcinogenesis." As in the examples pro-
vided by the studies on myeloid leukaemic
cells, I believe that the Morris hepatomas
are blocked in various sequences in the
process of cell differentiation, and that
several of them, if not all, contain a
characteristic proportion ofcells that leave
the proliferative poolpermanently, moving
along the pathways of differentiation to
approach, but in general not to attain, the
final adult state. This is what is meant by
the phrase "partially blocked ontogeny".
Our insight into the meaning of the find-
ings in transplantable hepatomas and
autochthonoushepatomas requires a closer
look at the changing phenotypic expres-
sion seen in foetal and neonatal liver, in
regenerating liver after partial hepatec-
tomy and precancerous liver (Walker and
Potter, 1972) (Fig. 8).
The working hypothesis for our studies
on carcinogenesis and differentiation in rat
liver is illustrated in Fig. 9 and in Table I.
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TABLE I.-Speculatit
classes of rat hepato
age of the animal
Stage
Age
Birth
60 Days
Adult
Old Adult
Old Adult with
regenerated
liver
GoEH
70
20
10
5
10
* See Fig. 9. The Go stag(
can enter G1, while the GT
hepatocyte; H, intermedia
hepatocyte.
t Based on data of Stocl
In Fig. 9 I propose thl
cells differentiate alo
can be characterized
or secretory proteins
liferation can be ini
movement from Go to
point along this pathw
are indicated, but in fact there may be
,42iiniZiZZ~ many stages between GoEH and GoH with
REGENERATING variable alpha-foetoprotein (AFP) pro- RE-ONTOGENY duction, accounting for the variability of
] ~4iL E AFP production byMorris hepatomas (Sell
*AL ADULT LIVER and Morris, 1974), and between GOH and
ZYMES ISOZYMES GTBD accounting for the occurrence of
NPRECEROUS gamma-glutamyl transpeptidase (GGT) in RE-ONTOGN some hepatomas and foci but not in others
(Richards and Potter, 1978; Pitot et al.,
HEPATOMA CLONES 1978). I believe that the available evidence
00 5123C 9618A supports the hypothesis that the propor-
J _LJ i_ tion of cells that can be assigned positions
TISSUE along the Go pathway varies with age and
CU TSSUES chemical treatment. New methodologies
ystems available for have been introduced by Laishes and
eAdontogenyhypothe- Farber (1978) and Laishes et al. (1978).
portionofthesquares Laishes and Farber have carried out
of3 pyruvate-kinase transfer experiments reminiscent of the leonatal, adult, and
I in 3 transplantable spleen-colony assays ofTill and McCulloch
ker and Potter (1972) (1961). After generating presumptive pre-
n Pergamon Press).
ia pyruvate kinase malignant or altered cells in the liver of
, but the enzyme is donor rats receiving acetyl-aminofluorene
ibout the 5th day of (2-AAF) and othertreatment,theyisolated
ldle square in above suspensions of single hepatocytes and
injected them into the portal vein of syn-
geneic recipients. On the 10th day follow-
ve distribution of 4 ing transfer, they killed the recipients and
cytes according to the counted the colonies that could be identi-
fied in liver sections stained histochemic-
of differentiation* ally for GGT. Presumably the altered cells
,_____ have been blocked at some point after the
GoH GoAH GTAH genes for GGT became available (see Fig.
20 10 0 9). Laishes et al. (1978) have shown that in
30 50 0 primary cultures of hepatocytes isolated
15 70 5 from normal adult liver, all the cells are
5 20 70t sensitive to the cytotoxic effects of afla-
10 57 23t toxin B1 at concentrations that apparently
do not damage a high percentage of the
e is defined as a stage that cells from nodules produced by 2-AAF.
r stage cannot. EH, early This test may be a way of quantifying the
te hepatocyte; AR, adult percentage of cells in the categories sug-
ker and Heine (1971). gested in Fig. 9.
Table I illustrates how the labels in Fig.
at parenchymal liver 9 might be distributed according to the
ng a pathway that age of the animal. The Table is simply
by certain enzymes another description of the model, and the
and that cell pro- exact numbers need to be revised as better
ltiated (in terms of data become available. However, a begin-
G1) at more than one ning can be made at this time using known
ay. Two such points parameters.
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Fetoprotein)
A
G2~
S*--O,1
(Pyruvate ki
(dcmp deam
(Gamma-Glutamyl
Transpeptidase)
, BD _,9 -- I_L ueatn
I
GT
H
>Death
(Glucokinase)
(Pyruvate kinase 1)
(Albumin)
FiG. 9. Oneogeny as partially blocked ontogeny. Model proposing two main classes of proliferating
parenchymal liver cells (luring liver ontogeny and liver regeneration, with proposedl partial blocks
indicate(d by asterisks to account for phenotypic diversity of hepatomas. Superscripts as follows:
EH, early hepatocyte, main class in foetal liver; H, intermediate hepatocyte, actively proliferat-
ing in young growing rat or in regenerating liver; AH, adult hepatocyte, not actively proliferating;
BD, bile-duct epithelium, believed to be in a terminal stage ofdifferentiation (GTBi)). Other symbols
as in Figs. 2 and 3. It is clear that reversal from GoAH to GOH and G1H can occur, and it is possible
that reversal from Go" to GoEH can occur. Thus it may be that the BD cells are derived from EH
rather than H cells. Pro(dtucts in parentheses are possible markzers for EH, H, AH, an(l BD cells. See
text an(l Tables I and II.
Alpha-foetoprotein and albumin production
One ofthe parameters that is important
in testing the model illustrated by Fig. 9
and Table I is cai-foetoprotein. DeNechaud
and Uriel (1971) have determined the level
of AFP in serum of rats from before birth
until 36 days of age, and in serum from
rats with livers undergoing compensatory
hyperplasia after CC14 damage. Secretion
ofAFP declined from a maximum at birth
to nearly zero on the 32ndday. Duringthis
time serum albumin increased reciprocally,
and reached its maximum plateau between
20 and 32 days after birth. Similar findings
were reported by Watabe et al. (1972)
whose data are shown in Fig. 10 as repro-
duced by Hirai et al. (1973). Studies by
Sell et al. (1974) also demonstrate the rapid
decrease in AFP production by the livers
of newborn rats. All 3 groups place the
decline to the adult level of less than 0.1
[kg/ml at around 28 to 36 days of age.
Tsukada and Hirai (1975) have examined
the production of albumin and AFP
production during the cell cycle in 2
hepatoma clones in synchronous culture.
Synthesis of both occurred in late G1 and
early S, declined in late S to zero in G2,
M1 and early G. Immunofluorescent stain-
ing, showed that only a few cells were
stained and that AFP and albumin stains
were in different cells (coloured slide,
courtesy of Dr Y. Tsukada). I feel that
the available data (Tsukada and Hirai,
1975; DeNechaud and Uriel, 1971; Watabe
et al., 1972; Hirai et al., 1973; Sell et al.,
1974) support the model described in Fig.
9 and Table I.
Further support comes from studies on
AFP production by regenerating liver as a
function of the age of the rat at partial
hepatectomy (DeNechaud and Uriel, 1971;
Sell et al., 1974). According to the model,
the proportion of early hepatocyte (EH)
parenchymal cells to adult hepatocyte
(AH) parenchymal cells decreases withage.
It is proposed that after hepatectomy, the
pool of EH cells divides and matures to
the H class, producing AFP in proportion
to the number of El cells at the age of
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operation. Concurrently, the AH cells in
Go move back to G1 and proliferate with-
out producing AFP. DeNechaud and Uriel
(1971) reported that the reappearance of
AFP caused by liver regeneration in young
rats "cannot be provoked by CC14 in rats
Days birth
FIG. 10. Synthesis of serum albumin in rela-
tion to synthesis of o-foetoprotein during
ontogeny in foetal and neonatal rats.
(Data from Watabe et al. (1972) an(d Hirai
et al. (1973) with permission of the Japan
Scientific Societies Press and Professor
H. Hirai.) Data as %0 of total protein.
The (iata support the model presented in
Fig. 9 an(d Table I, in that the curves
may reflect the changing ratio of GoEH
to (GoH+GoAH). Immunofluorescence stainl-
ing in hepatoma cultures shows that only a
few cells were stained, for one or the other
protein. During most of the cell cycle,
neither protein was prodluced in cultures
examined (Hirai et al., 1973). See Text.
older than 7 weeks". They further sug-
gested that "The resurgence of oxFP in
hepatic injury of newborn rats and young
rats is a consequence of the enhanced
activity of some incompletely differen-
tiated cell clones." Sell et al. (1974) carried
out partial hepatectomy instead of using
CC14 and used male rats at the ages of 5
and 7 weeks and adult males at about
300 g body weight. The decrease in AFP
production with age wasstriking, andthere
was no significant production in the adults.
They commented that "It is possible that
a 'special' liver cell produces oaFP such as
a transitory post-mitotic cell" and ".
most hepatic parenchymal cells, particu-
larly of the foetal rat, have the capacity to
synthesize nlFP" (italics added). Again
the data support the model of 2 classes
of proliferating parenchymal cells.
Blocks in the process of differentiation
couldexplain the factthatsomehepatomas
secrete large amounts of AFP while others
secrete essentially inone and all values
between 04 I jg/mland 10,000arerepresent-
ed (Sell and Morris, 1974). I suggest that
the AFP-secretory hepatomas are prolife-
rating largely at the EHstage, withcertain
other hepatomas partially blocked and
moving into the H and AH classes to some
extent, and still others blocked prior to
the stage at which AFP is produced. This
description seems to fit the data of Tsu-
kada and Hirai (1975) who found pheno-
typic heterogeneity within the 2 hepatoma
clones with cells that were negative (due
to position in cell cycle) and cells that were
positive for either AFP or albumin (due, in
my opinion, to their position in the par-
tially blocked programme of parenchymal-
cell ontogeny).
Still another line of evidence suggesting
de-repression and reversal from GoH to
GoEH (Fig. 9) by carcinogens is based on
AFP secretion by preneoplastic livers,
which has been widely observed prior to
appearance of actual nodules (Kroes et al.,
1975). Few studies have been carried out
on AFP production by hepatomas or pre-
neoplastic liver as a function ofage atfirst
exposure to carcinogen but a relevant study
was carried out by Kroes et al. (1975) who
found that "Rats started on aflatoxin B1
when 6 weeks old had more mixed liver
tumours with neoplastic hepatocytes and
bile ducts and higher AFP levels than did
rats started at 26 weeks". Again the model
(Fig. 9) appears to be supported.
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Deoxycytidylic dearninase as a markerfor
the cycling early hepatocyte (EH)
Thymidine triphosphate is an essential
building block for the synthesis of DNA,
and it is of some interest that there are 3
alternative pathways leading to the forma-
tion of this compound. Number one is the
well-known salvage or preformed pathway
which begins with thymidine, the com-
pound used in so many cell kinetic studies
since Howard and Pelc (1953). In compe-
tition with the salvage pathway are 2 de
novo pathways, both of which involve re-
duction of ribotides to deoxyribotides.
What is unexplained is that in one instance
deoxyuridylic acid (dUMP) is formed di-
rectly (Pathway 2) while in the other case
it is formed indirectly, that is, by the
deamination ofdeoxycytidylic acid (dCMP)
(Pathway 3).
TABLE II.-Deoxycytidylic dearmina&se in
carious tissues
Tissule
Normal liver
Foetal liver (17 20 (lays)
Regenerating livei (48 h)
Dunning LC18 hepatoma
Novikoff hepatoma
Liver, V3'-Me-DAB dliet, 22 dlays
36 (lays
27 clays-7
Control diet, 15 days
clCMP
cleaminase
activity*
0, 0,
59, 20
0, 1, 5
O, O, 0, 0
70, 59, 66, 41
11, 11, 11, 8
7, 5, 8, 5
0, 0, 0, 04
* Activity in ,umol dUMP formed/h/g tissue (Path-
wav :3) (lata from Pitot an(l Potter (1960).
ICMP pathways
TTP-- DNA
(2) T
ITDP > (duNIP > TMP
)k )k
(Foetal liver) (3) (1)
(CDP > (ICMP TdR
What is proposed here is that the in-
direct Pathway 3 (Table II) is not essen-
tial for DNA synthesis in all proliferating
liver cells and that dCMP deaminase is, in
fact, a marker for an early stage of paren-
chymal liver-cell ontogeny, the cell cycle
for the ER or Early Hepatocytes shown
in Fig. 9. It was shown by Pitot and Potter
(1960) that normal adult and regenerating
liver had very little activitycomparedwith
foetal liver (Table II). Moreover, the Novi-
koffhepatoma had very high activitywhile
the Dunning hepatoma had almost none.
Preneoplastic liver also had elevated levels
of dCMP deaminase (Pitot and Potter,
1960) at times that compare with times
of elevated AFP (Kroes et al., 1975).
As the methods for measuring activity
became more sensitive, the enzymebecame
detectable in normal liver, and slight in-
creases were found in regenerating liver
and various hepatomas as shown by Maley
and Maley (1960; 1961a, b) Sneider and
Potter (1969) and Sneider et al. (1969) but
the spread between high and low values
remains.
The relative contribution of the 2 path-
ways (Nos. 2 and 3 in Table II) in
regenerating liver cannot be judged by the
presence of dCMP deaminase (Maley and
Maley, 1960; 1961a, b; Sneider et al., 1969;
Sneider and Potter, 1969) without a mea-
sure of the competing pathway. An en-
tirely different inethod was used by Hecht
and Potter (1956) who uised labelled orotic
acid as a precursor, and measured ratios of
labelled pyrimidine nucleotides in DNA.
Further studies by Crone and Itzhaki
(1965) supported our findings, and they
concluded with us that the indirect path-
way from dCMP to dUMP played a minor
role in regenerating liver.
Thus, the small increase in dCMP de-
aminase in regenerating liver might be
occurring in a population of early hepato-
cytes, as in Fig. 9, and the variation be-
tween hepatomas mightdependonwhether
the block in ontogeny occurred at the EH
or the H level in Fig. 9. Further studies on
regenerating liver and preneoplastic liver
at various ages with the aid of immuno-
fluorescent techniques are needed to show
whether dCMP deaminase in these tissues
is restricted to a minority population of
hepatocytes whose numbers decrease as
the age of the rat increases, just as seems
to be the case for AFP secretion (De-
Nechaud and Uriel, 1971; Sell et al., 1974).
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FIG. 11.-Early events in regenerating rat liver during transition from GoAII to GiH: the increase in
amino-acid-transport activity. Data from Wondergem and Potter (to be published). Amino-acid-
transport activity was studied by the preloading technique using (x-amino isobutyric acid (AIB).
The "distribution ratio" is the tissue value divided by the blood value for each animal. Blood values
were quite constant throughout.
Phenotypic diversity in the hormonal control
of amino-acid transport
Amino-acid-concentrating ability (i.e.,
active transport) can be conveniently
studied with the aid of radioactive oa-
aminoisobutyric acid (AIB) because this
compound is neither oxidized to CO2 nor
incorporated into protein, and because it
is actively transported. Since AIB is slowly
excreted, it can be injected into the animal
24 h prior to killing and the steady-state-
equilibrium values between tissue and
blood can be determined under a variety
of conditions. It appears that the amino-
acid transport of the early hepatocyte
(EH in Fig. 9 and Table I) may be less
responsive to glucagon than the adult
hepatocyte (AH) and that various hepa-
tomas may have properties resembling
EH, H, or mixtures of the types repre-
sented in Fig. 9.
Amino-acid transport in regenerating liver
After numerous experiments on re-
generating and neonatal liver and on
various hepatomas, we recently returned
to the regenerating liver system in order
to study the earliest events during the
transition from GoAH to GoH to G1H (Fig.
9). AIB was injected 24 h earlier and the
distribution ratio was determined at
various times up to 24 h after the surgery
(Wondergem and Potter, to be published).
Fig. 11 shows that after a short lag there
was a marked increase in the AIB con-
centration in the livers by 3 h and that
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FIG. 12. Delayed increase in amino-acid(-
transport activity after early rise in
cyclic AMP in primiary cultures of non-
eplicating adult rat liver parenchymal
liver cells after treatment with dexame-
thasone an(d glucagon. (Data from Pariza
et 1l., 1976.) The (lashe(l line shows the eaily
increase in cAlIP in the cultures contain-
ing Dexamethasone (DEX) andl Glucagon.
The solid lines show the increase in AIB ((x-
aminoisobutyric aci(l) transpoirt activity
(initial rates at time ind(licated). A, DEX
+ glucagon; A, glucagon only; 0, DEX
only; 0, medium only. All ctultures con-
taining DEX were pretreatedl for 12 h with
DEX prior to zero time.
elevated levels were maintained for the
entire subsequent period studied. Not
shown is the fact that parallel increases
were observed in the activity of ornithine
decarboxylase, and from the literature
similar early increases in prostaglandin
(blocked by indomethacin) (McManus and
Braceland, 1976) and serum glucagon
(Leffert et al., 1976) were seen. These data
suggest a possible connection between
amino-acid transport and proliferation of
liver cells, and suggest that regenerating
liver may be responsive to glucagon. In
the context of Fig. 9 and Table I, we may
ask whether the (OEH cells in liver fail to
respond to glucagon in terms ofamino-acid
transport, and whether these cells are the
precursors of hepatomas that fail to re-
spond to glucagon.
Amino-acid transport in primary liver
cultures
Procedures for the preparation of sus-
pensions of parenchymal liver cells essen-
tially free from other cell types have been
developed. These cells have been placed in
cell cultures as monolayers on a collagen
film and used for the study ofAIB uptake
(Pariza et al., 1976). In cells pretreated
with dexamethasone a marked increase in
AIB transport was produced by glucagon
(Fig. 12) with a short lag quite similar to
that observed in vivo (Fig. 11). Glucagon,
with or without dexamethasone, produced
a striking increase in the concentration of
cyclic AMP within a few minutes (Fig. 12).
Although the adult-liver cells in cultured
monolayers responded to glucagon with
increased AIB transport in a manner com-
parable to that observed in regenerating
liver in vivo, they did not proceed to the
S phase (DNA synthesis) and did not pro-
liferate. They appear to have remained at
the (oAH stage shown in Fig. 9. However,
Leffert et al. (1976) have treated primary
liver monolayers in their standard system,
and demonstrated striking increases in
thymidine incorporation into DNA by the
addition of prostaglandin E. Thus, the
data from experiments in vitro appear to
be approaching the in vivo data. Again, as
before, the questions ofthe relative contri-
butions and relative initial concentrations
of GoEH, GoH and GOAH cells remain un-
answered, and the systematic study ofcells
from different ages of rats, with quantita-
tion based on the identification of indivi-
dual cells, remains for thefuture. However,
helpful clues come from studies on neo-
natal rats and on transplantable Morris
hepatomas.
Amino-acid transport in neonatal liver
Soon after the preloading technique for
studying AIB was developed, we under-
took studies on rats up to about 20 days
of age. It was shown that AIB and cyclic
AMP responses to glucagon were measur-
able at 0 to 2 days but that marked in-
creases in response occurred between 2
and 10-20 days (Reynolds et al., 1971;
Butcher and Potter, 1972; Butcher et al.,
1972). The data are compatible with the
model presented in Fig. 9 and Table I, if
it is assumed that the EH have basic levels
of amino-acid transport and cyclic AMP
that are not responsive to glucagon.
Anmino-acid transport in Morris hepatomras
With the background of information
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FIG. 13. Two classes of Morris hepatomas basedl on amino-acid-transport activity and cAMP
response to glucagon in vivo (Butcher et al., 1972) compared with response of tyrosine-amino-
transferase activity (Scott et al., 1972) (with permission from Cancer Res.). Numbers refer to Morris
hepatoma lines. Solid symbols: data from animals at zero time with respect to glucagon injection.
Open symbols: data 15 min after injection (for cAMP) or at 3-5 h in other animals (for AIB dis-
tribution ratio or tyrosine-aminotransferase assays). Distribution ratio is derived from tissue/
blood for each animal, 24 h after loading with AIB. The box in the chart on the right belongs in
the area outlined by (lashed lines.
from regenerating liver, primary liver
monolayers, and neonatal liver, we can
now turn to data on 11 different lines of
Morris hepatomas, some of which were in
adrenalectomized hosts. The parameters
studied were cyclic AMP (Butcher et al.,
1972) tyrosine aminotransferase (Scott et
al., 1972) and AIB transport (both papers)
in animals treated with glucagon in com-
parison with untreated controls. All the
parameters respond to glucagon in normal
adult rat livers, which presumably have a
majority of GOAH cells, while responses to
glucagon are considered to be undeveloped
or absent in GoEH or G1EH cells.
The data turned out to be quite clear-
cut (Fig. 13). Below an AIB distribution
ratio of 5 at time zero inuntreated animals,
all hepatomas responded to injected glu-
cagon with an increase in cyclic AMP that
was in some cases equal to or greater than
that of normal adult liver, and the resting
values were similar to that for restingadult
liver. These hepatomas thus approach the
concept of minimal deviation with respect
to adult liver. However, many hepatoma
lines had initially elevated AIB ratios (10
to 30 compared to adult liver at about 3)
and none of these hepatomas responded to
glucagon with an increase in cAMP (Fig.
13). Unexplained is their response with
tyrosine aminotransferase, which was
striking in some cases (Fig. 13). The data
suggest that the glucagon responders have
cells that include a greater proportion of
H and AH cells, as in adult liver, in keep-
ing with their "differentiated" classifica-
tion, while the non-responders are "less
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Fic.. 14. AIB (listribution ratios in auitochthonous neoplastic nodtules compared with adjacent
host, liver in rats, using inidividual serum AIB levels (X) for r-eference. (From Kelley andI Potter
(1977) with permission from Academic Press, Inc.) Tumours were induced with AAF at 002oo
in the diet for 30 days, followed by 0-050o phenobarbital in the diet for nearly 300 days. Circles,
males; triangles, females. Closed symbols, distribution ratios in host livers assayed in ascending
order. Open symbols, distribution ratios in several individual nodules arranged in vertical line
with the closed symbols for the corresponding host liver. X, the absolute values for the correspond-
ing serum samples that were used to calculate the (distribution ratios. The (data on serum samples
establish that the dlistribution ratios are independent of the observed variations in the serum.
The distribution ratios of all the hepatomas had a mean of 2-95+ 0.09 s.e., placing them in the
middle of the lowest transplantable.hepatoma values shown in Fig. 13.
differenitiated" anid conitaini more of the
ER-type cells. These latter cells have be-
come "de-repressed" with respect to AIB
transport, and in this respect are unlike
the liver cells in newborn liver.
Amino-acid transport in a ttochthonous
neopla,stic liver nodales
We recently attempted to produce the
minimal-deviation type of hepatoma by
the use of a minimal exposure to a liver
carcinogen, and thus far have published
only the data on the AIB ratios (Kelly and
Potter, 1977). A total of 123 hepatomas
were dissected from 43 host livers, one day
after the injection ofradioactive AIB. The
distribution ratios of each individual prim-
ary nodule are shown in Fig. 14. Despite
great inidividuial variation between niodules,
even within asingle liver, the mean value is
like thosetransplantablehepatomas that in
the uninjected animals had AIB ratios be-
low that ofthe adult control liver (Fig. 13).
Despite the uniformity of AJB ratios and
similarity to control liver seen in all the
Morris hepatomas, these autochthonous
hepatomas showed marked deviations
from the adjacent selected samples of host
liver (these data will be published later).
CONCLUSION
Ini this lecture I have suggested that
certain cells in the liver of an animal
treated with a carcinogen can develop into
a hepatoma in which there are cells with
I.r
x
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phenotypic variations that correspond to
different stages in the differentiation ofthe
cell lineages in normal liver. I have empha-
sized the concept of "partially blocked
ontogeny" as a means of expressing the
view that a highly differentiated hepatoma
may contain a sizeable fraction of cells
that are in what I have referred to as Go
and GT stages, that is, they may have
moved out of the proliferative cycle and
differentiated to variable extents along
the several simultaneous pathways taken
by normal hepatocytes.
It was emphasized that the manystudies
indicating similarities between cancer tis-
sue and foetal tissue take on significance
in the phrase "oncogeny is blocked onto-
geny", the point being that cancer tissue
does not resemble foetal tissue, in so far as
it is unable to follow the normal course of
terminal differentiation in the course of
which the adaptive needs of the whole
organism are served. In this context I
would like to put an end to the labelling of
the products of differentiated cells as
"luxury molecules" (Pierce et al., 1974)
and to begin to label them for what they
are, namely, "organism-serving mole-
cules". In contrast to the balance between
production of "self-serving" and "organ-
ism-serving" molecules in normal tissues,
it is now clear that although many neo-
plasms have differentiated to the point
that they are capable of producing one or
several organism-serving molecules, they
have in common the inability to carry on
this activity in the orchestrated adaptive
way that characterizes normal tissue in
normalsteady-state oradaptive conditions.
In the present discussion I have chosen
to enlarge the Howard and Pelc (1953)
concept of the cell cycle (with the Go
adjunct proposed by Lajtha, 1963) so as
to indicate the phenotypic diversity of Go
cells that are compatible with a return to
G1 and S in the proliferative cycle. In order
to clarify the existence of a fraction of the
cell population that does not conform to
the Go definition, in that they are unable
to return to G1, I have proposed the desig-
nation GTfor all those cells in the more ad-
vanced stages of terminal differentiation,
presumably corresponding to the Q frac-
tion described by Menidelsohn and Dethlef-
son (1973) and by Steel et al. (1966).
The concept of "partially blocked on-
togeny" seen in these terms is a further
development of the "blocked ontogeny"
hypothesis. It is not required that all the
descendants of a neoplastic cell must re-
side at some pointintheproliferative cycle.
Indeed, even the most bizarre aneuploid
neoplasms may produce one or several
kinds of molecule in what has been called
up to now the luxury-molecule category
and that I now insist is the organism-
serving category. On this basis I now pro-
pose the dictum that any neoplasm that
produces an organism-serving molecule is
an example of "partially blocked ontogeny".
Most interesting from the standpoint of
understanding the relation between car-
cinogenesis and differentiation are the
minimally deviated neoplasms in which
the line between the normal and the neo-
plastic is less and less obvious. In these
cases the tumour is not fully autonomous,
but merely "autonomous enough" under
the given conditions, and as mentioned by
Osgood (1957, 1959), by Pierce et al. (1974)
and by Fibach et al. (1973), it might be
possible to tip further the balance from
proliferation to differentiation so as to
achieve therapeutic control.
In this lecture I have suggested that
those of us not familiar with the studies
on haemopoiesis have much to learn from
current progress in that field, which seems
to epitomize the feedback relations be-
tween differentiation, proliferation and
neoplasia. At the same time I have empha-
sized that research on chemical carcino-
genesis in liver is now ready with a variety
of experimental approaches to study
highly differentiated hepatomas, preneo-
plastic foci, and cell cultures that can
further elucidate the relationship between
differentiation, proliferation andneoplasia.
In a larger sense, I have endeavoured to
justify my Tokyo statement that by 1978
"a comprehensive and penetrating under-
standing of the molecular and biological
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nature of cancer" would be near at hand.
Some ofthe uncertainties in differentiation
have been mentioned by Coleman (1976)
in reviewing Cell Cycle and Cell .Differenti-
ation by Reinert and Holtzer as follows:
"Itis onceagainapparentfromthisvolume
that cell differentiation and the cell cycle
are intriguingly coupled, but experimental
evidence so far provides no mechanistic
basis for choosing between the relatively
cataclysmic model of quantal mitosis and
a model of more gradual reprogramming
accompanying cyclic changes in the state
of the genetic material."
On the positive side, we have the pro-
posals by Holliday and Pugh (1975) who
developed a model of development based
on "a continual interaction between cyto-
plasmic enzymes and DNA sequences ...
these cytoplasmic components are, of
course, usually derived from the activity
of genes at some earlier stage in develop-
ment... The use ofdevelopmentalmutants
is probably essential, since by comparison
with wild-type organisms it may be pos-
sible to identify the nature of their bio-
chemical defects [compare with Lotem
and Sachs (1974) above]. ... We proposed
that the same ordered control of the tran-
scription ofgenes could be achieved by the
methylation of bases, without changes in
sequence." They concluded with the idea
of"repeated sequencesofcontrollingDNA,
which could dissociate from and reassoci-
ate with several chromosomal sites by
means ofgeneticrecombination. Whatmay
now be needed is an examination of these
genetic elements in a higher organism in
which both biochemical andgeneticstudies
can be undertaken."
At this point I must conclude mylecture
as in a novel in serial form: "to be con-
tinued". However, I must say that the
need for synthesis, for the conversion of
knowledge to wisdom, has never been
greater, owing to the volume of data, and
I must re-emphasize the fact that neither
I nor anyone else is capable of achieving
the needed synthesis alone and unaided
(Potter 1956). Thepresent effort according-
ly invites needed discussion.
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